Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ.
Transplantation. 2023 Mar 1;107(3):782-791. doi: 10.1097/TP.0000000000004343. Epub 2022 Oct 28.
Nocardia is an environmental pathogen with a predilection for causing opportunistic infections in immunocompromised patients, including solid organ transplant (SOT) recipients. Although risk factors have been identified for developing nocardiosis in this population, little is known regarding clinical factors resulting in poor outcomes. We evaluated a cohort of SOT recipients with nocardiosis for associations with 12-month mortality.
We performed a multicenter retrospective cohort study of adult SOT recipients diagnosed with culture-confirmed nocardiosis from 2000 to 2020. Patients were followed for 12 months after diagnosis, unless abbreviated by mortality. Multivariable Cox regression was performed to analyze associations with 12-month mortality. A subgroup analysis of patients with disseminated nocardiosis was performed to analyze treatment variables.
A total of 125 SOT recipients met inclusion criteria; 12-month mortality was 16.8%. Liver transplantation (hazard ratio [HR] 3.52; 95% confidence interval [CI] 1.27-9.76) and time from symptom onset to presentation (HR 0.92/d; 95% CI 0.86-0.99) were independently associated with 12-month mortality, whereas disseminated infection was not (HR 1.23; 95% CI 0.49-3.13). No treatment-specific factors were significantly associated with mortality in 33 patients with disseminated nocardiosis, although survivors had a higher rate of linezolid use.
This study identified 2 independent associations with 12-month mortality, representing demographics and infection severity. Disseminated infection was not independently associated with poor outcomes, and specific sites of infection may be more important than dissemination itself. No treatment-specific factors were associated with mortality, though this analysis was likely underpowered. Further study of treatment strategies based on specific Nocardia syndromes is warranted.
诺卡氏菌是一种环境病原体,易在免疫功能低下的患者中引起机会性感染,包括实体器官移植(SOT)受者。尽管已经确定了该人群发生诺卡氏菌病的危险因素,但对于导致不良结局的临床因素知之甚少。我们评估了一组患有诺卡氏菌病的 SOT 受者,以评估其与 12 个月死亡率的关系。
我们对 2000 年至 2020 年期间确诊为培养阳性的诺卡氏菌病的成年 SOT 受者进行了一项多中心回顾性队列研究。患者在诊断后随访 12 个月,除非因死亡而缩短随访时间。采用多变量 Cox 回归分析与 12 个月死亡率相关的因素。对患有播散性诺卡氏菌病的患者进行亚组分析,以分析治疗变量。
共有 125 名 SOT 受者符合纳入标准;12 个月死亡率为 16.8%。肝移植(风险比 [HR] 3.52;95%置信区间 [CI] 1.27-9.76)和从症状出现到就诊的时间(HR 0.92/d;95%CI 0.86-0.99)与 12 个月死亡率独立相关,而播散性感染则不相关(HR 1.23;95%CI 0.49-3.13)。在 33 例播散性诺卡氏菌病患者中,没有发现特定的治疗因素与死亡率显著相关,尽管存活者使用利奈唑胺的比例较高。
本研究确定了与 12 个月死亡率相关的 2 个独立因素,分别代表了人口统计学和感染严重程度。播散性感染与不良结局无独立相关性,感染部位可能比播散本身更重要。没有发现治疗因素与死亡率相关,但这种分析可能存在检验效能不足。需要进一步研究基于特定诺卡氏菌综合征的治疗策略。